- The P-III BRAVE-AA2 study involves assessing Baricitinib (2mg & 4mg, qd) vs PBO in 546 adults with a SALT score ≥ 50 (i.e., who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least 6mos. but no >8yrs.
- The P-III study met its 1EPs @36wks. and demonstrated significant improvement in scalp hair regrowth. The findings from additional P-III study will be available in H1’21
- Baricitinib is an oral JAK inhibitor and commercially available as Olumiant in the US and 70 + countries for mod. to sev. active RA. The therapy is also approved for AD in the EU and Japan and has received the US FDA’s BTD for AA
Click here to read full press release/ article | Ref: Lilly | Image: Bloomberg